Gerald P Linette, MD, PhD
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Graduate Group Affiliations
Contact information
University of Pennsylvania
Center for Cellular Immunotherapies
3400 Civic Center Blvd
SPE 8-102
Philadelphia, PA 19104
Center for Cellular Immunotherapies
3400 Civic Center Blvd
SPE 8-102
Philadelphia, PA 19104
Office: 215-573-7032
Email:
glinette@upenn.edu
glinette@upenn.edu
Education:
BS (Biology)
St. Joseph's University , 1980.
PhD (Microbiology )
Georgetown University School of Medicine , 1990.
MD
Georgetown University School of Medicine, 1990.
Permanent linkBS (Biology)
St. Joseph's University , 1980.
PhD (Microbiology )
Georgetown University School of Medicine , 1990.
MD
Georgetown University School of Medicine, 1990.
Description of Clinical Expertise
1. Medical Oncology2. Melanoma and other advanced skin cancers
3. Neuro-Oncology
Description of Research Expertise
Human Cancer Immunology is the focus of our laboratory and clinical efforts.The development of a systematic approach to identify and validate cancer neoantigens is a primary interest of our research laboratory. In collaboration with experts in cancer genomics, we have created a bioinformatics pipeline to identify tumor-specific missense mutations which encode neoantigenic peptides. Our team has successfully applied this strategy to develop the first test of personalized cancer vaccination in humans with melanoma. Ongoing proof-of-concept trials aim to test neoantigens as targets for various immunotherapy strategies in melanoma and other solid tumors. In particular, our work aims to characterize the functional and phenotypic landscape of vaccine-elicited T cells using state-of-the-art molecular technologies.
A related interest is the development of cellular therapies for cancer. We are currently exploring the development of neoantigen-specific T cell therapy for use in patients. We work collaboratively with research groups in order to find novel solutions to overcome the inherent obstacles created by the tumor microenvironment. The long term goal is to advance and test personalized medicine based approaches in cancer patients. For more information, please see the Center for Cellular Immunotherapies home page.
Selected Publications
Bear AS, Nadler RB, O'Hara MH, Stanton KL, Xu C, Saporito RJ, Rech AJ, Baroja ML, Blanchard T, Elliott MH, Ford MJ, Jones R, Patel S, Brennan A, O'Neil Z, Powell DJ Jr, Vonderheide RH, Linette GP, Carreno BM.: Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. J Clin Invest 134: e175790, Sep 2024.Linette GP, Bear AS, Carreno BM.: Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations. Clin Cancer Res 30: 2017-2024, May 2024.
Chang JF, Wellhausen N, Engel NW, Landmann JH, Hopkins CR, Salas-McKee J, Bear AS, Selli ME, Agarwal S, Jadlowsky JK, Linette GP, Gill S, June CH, Fraietta JA, Singh N.: Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors. Cancer Immunol Res 12: 1136-1146, Sep 2024.
Migliorini D; Dietrich PY; Stupp R; Linette GP; Posey AD Jr; June CH: CAR T-Cell Therapies in Glioblastoma: A First Look. Clinical Cancer Research. 24(3):535-540, 2018 02 01 2018.
Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J.: Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. July 2017.
Hodi FS1, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA.: Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17(11): 1558-1568, Nov 2016.
Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, Griffith M: pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med 8(1): 11-19, Jan 29 2016.
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS.: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21): 2006-17, May 21 2015.
Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P.: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17(10): 1374-1385, Oct 2016.
Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, Linette GP.: A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348(6236): 803-8, May 15 2015.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ.: Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med. 363(8): 711-23, Aug 19 2010.
Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, Aft RL, Cornelius LA, Trinkaus KM, Linette GP.: IL-12p70 producing patient DC vaccine elicits Tc1-polarized immunity. Journal of Clinical Investigation 123(8): 3383-94, Aug 2013.